1 |
Wang, Q., Y. Ji, X. Wang, and B. M. Evers. 2000. Isolation and molecular characterization of the 5'-upstream region of the human TRAIL gene. Biochem. Biophys. Res. Commun. 276, 466-471.
DOI
ScienceOn
|
2 |
Perianayagam, M. C., N. E. Madias, B. J. Pereira, and B. L. Jaber. 2006. CREB transcription factor modulates Bcl2 transcription in response to C5a in HL-60-derived neutrophils. Eur. J. Clin. Invest 36, 353-361.
DOI
ScienceOn
|
3 |
Pitti, R. M., S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore, and A. Ashkenazi. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690.
DOI
|
4 |
Rychahou, P. G., C. A. Murillo, and B. M. Evers. 2005. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery 138, 391-397.
DOI
ScienceOn
|
5 |
Secchiero, P., A. Gonelli, E. Carnevale, D. Milani, A. Pandolfi, D. Zella, and G. Zauli. 2003. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107, 2250-2256.
DOI
ScienceOn
|
6 |
Song, J. J., J. Y. An, Y. T. Kwon, and Y. J. Lee. 2007. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J. Biol. Chem. 282, 319-328.
DOI
|
7 |
Spierings, D. C., E. G. de Vries, E. Vellenga, F. A. van den Heuvel, J. J. Koornstra, J. Wesseling, H. Hollema, and J. S. de. 2004. Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem. 52, 821-831.
DOI
ScienceOn
|
8 |
Takeda, K., Y. Hayakawa, M. J. Smyth, N. Kayagaki, N. Yamaguchi, S. Kakuta, Y. Iwakura, H. Yagita, and K. Okumura. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7, 94-100.
DOI
ScienceOn
|
9 |
Tanaka, H., K. Yoshida, H. Okamura, H. Morimoto, T. Nagata, and T. Haneji. 2007. Calyculin A induces apoptosis and stimulates phosphorylation of p65NF-kappaB in human osteoblastic osteosarcoma MG63 cells. Int. J. Oncol. 31, 389-396.
|
10 |
Tao, K. S., W. Wang, L. Wang, D. Y. Cao, Y. Q. Li, S. X. Wu, and K. F. Dou. 2008. The multifaceted mechanisms for coffee's anti-tumorigenic effect on liver. Med. Hypotheses 71, 730-736.
DOI
ScienceOn
|
11 |
Levkau, B., K. J. Garton, N. Ferri, K. Kloke, J. R. Nofer, H. A. Baba, E. W. Raines, and G. Breithardt. 2001. xIAP induces cell-cycle arrest and activates nuclear factor-kappaB : new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ. Res. 88, 282-290.
DOI
ScienceOn
|
12 |
Martelli, A. M., P. L. Tazzari, G. Tabellini, R. Bortul, A. M. Billi, L. Manzoli, A. Ruggeri, R. Conte, and L. Cocco. 2003. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 17, 1794-1805.
DOI
ScienceOn
|
13 |
Mehta, K., P. Pantazis, T. McQueen, and B. B. Aggarwal. 1997. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 8, 470-481.
DOI
ScienceOn
|
14 |
Miller, D. M., D. A. Polansky, S. D. Thomas, R. Ray, V. W. Campbell, J. Sanchez, and C. A. Koller. 1987. Mithramycin selectively inhibits transcription of G-C containing DNA. Am. J. Med. Sci. 294, 388-394.
DOI
ScienceOn
|
15 |
Mohan, R., H. J. Hammers, P. Bargagna-Mohan, X. H. Zhan, C. J. Herbstritt, A. Ruiz, L. Zhang, A. D. Hanson, B. P. Conner, J. Rougas, and V. S. Pribluda. 2004. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 7, 115-122.
DOI
ScienceOn
|
16 |
Mucha, S. R., A. Rizzani, A. L. Gerbes, P. Camaj, W. E. Thasler, C. J. Bruns, S. T. Eichhorst, E. Gallmeier, F. T. Kolligs, B. Goke, and E. N. De Toni. 2009. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. Gut. 58, 688-698.
DOI
ScienceOn
|
17 |
Di, P. R. and G. Zauli. 2004. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J. Cell Physiol 201, 331-340.
DOI
ScienceOn
|
18 |
Lee, T. J., J. T. Lee, J. W. Park, and T. K. Kwon. 2006. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem. Biophys. Res. Commun. 351, 1024-1030.
DOI
ScienceOn
|
19 |
Lee, T. J., H. J. Um, D. S. Min, J. W. Park, K. S. Choi, and T. K. Kwon. 2009. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic. Biol. Med. 46, 1639-1649.
DOI
ScienceOn
|
20 |
Cretney, E., K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand- deficient mice. J. Immunol. 168, 1356-1361.
DOI
|
21 |
Ehrhardt, H., S. Fulda, I. Schmid, J. Hiscott, K. M. Debatin, and I. Jeremias. 2003. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22, 3842-3852.
DOI
ScienceOn
|
22 |
Fulda, S. and K. M. Debatin. 2004. Modulation of TRAIL signaling for cancer therapy. Vitam. Horm. 67, 275-290.
DOI
|
23 |
Gli-Esposti, M. 1999. To die or not to die--the quest of the TRAIL receptors. J. Leukoc. Biol. 65, 535-542.
|
24 |
Grosse-Wilde, A., O. Voloshanenko, S. L. Bailey, G. M. Longton, U. Schaefer, A. I. Csernok, G. Schutz, E. F. Greiner, C. J. Kemp, and H. Walczak. 2008. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest 118, 100-110.
DOI
ScienceOn
|
25 |
Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, and C. A. Smith. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.
DOI
ScienceOn
|
26 |
Almasan, A. and A. Ashkenazi. 2003. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337-348.
DOI
ScienceOn
|
27 |
Bodmer, J. L., P. Meier, J. Tschopp, and P. Schneider. 2000. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J. Biol. Chem. 275, 20632-20637.
DOI
|
28 |
Chen, X., K. Kandasamy, and R. K. Srivastava. 2003. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 63, 1059-1066.
|
29 |
Wang, W. Q., H. Zhang, H. B. Wang, Y. G. Sun, Z. H. Peng, G. Zhou, S. M. Yang, R. Q. Wang, and D. C. Fang. 2010. Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway. Mol. Diagn. Ther. 14, 155-161.
DOI
ScienceOn
|
30 |
Wang, X., W. Chen, W. Zeng, L. Bai, Y. Tesfaigzi, S. A. Belinsky, and Y. Lin. 2008. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol. Cancer Ther. 7, 1156-1163.
DOI
ScienceOn
|
31 |
Yokota, Y., P. Bargagna-Mohan, P. P. Ravindranath, K. B. Kim, and R. Mohan. 2006. Development of withaferin A analogs as probes of angiogenesis. Bioorg. Med. Chem. Lett. 16, 2603-2607.
DOI
ScienceOn
|
32 |
Yue, H. H., G. E. Diehl, and A. Winoto. 2005. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ. 12, 94-97.
DOI
ScienceOn
|
33 |
Zhang, L. and B. Fang. 2005. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12, 228-237.
DOI
ScienceOn
|
34 |
Van Geelen, C.M., E. G. de Vries, and J. S. de. 2004. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updat. 7, 345-358.
DOI
ScienceOn
|
35 |
Teitz, T., T. Wei, M. B. Valentine, E. F. Vanin, J. Grenet, V. A. Valentine, F. G. Behm, A. T. Look, J. M. Lahti, and V. J. Kidd. 2000. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6, 529-535.
DOI
ScienceOn
|
36 |
Tran, S. E., T. H. Holmstrom, M. Ahonen, V. M. Kahari, and J. E. Eriksson. 2001. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276, 16484-16490.
DOI
|
37 |
Um, H. J., J. H. Oh, Y. N. Kim, Y. H. Choi, S. H. Kim, J. W. Park, and T. K. Kwon. 2010. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. Chem. Biol. Interact. 186, 36-42.
DOI
ScienceOn
|
38 |
van Noesel, M. M., B. S. van, P. A. Voute, J. G. Herman, R. Pieters, and R. Versteeg. 2003. Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 38, 226-233.
DOI
ScienceOn
|
39 |
Wagner, K. W., E. A. Punnoose, T. Januario, D. A. Lawrence, R. M. Pitti, K. Lancaster, D. Lee, G. M. von, S. F. Yee, K. Totpal, L. Huw, V. Katta, G. Cavet, S. G. Hymowitz, L. Amler, and A. Ashkenazi. 2007. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13, 1070-1077.
DOI
ScienceOn
|
40 |
Wang, C., T. Chen, N. Zhang, M. Yang, B. Li, X. Lu, X. Cao, and C. Ling. 2009. Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1- JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB. J. Biol. Chem. 284, 3804-3813.
DOI
|
41 |
Jung, E. M., J. W. Park, K. S. Choi, J. W. Park, H. I. Lee, K. S. Lee, and T. K. Kwon. 2006. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis 27, 2008-2017.
DOI
ScienceOn
|
42 |
Ng, C. P., A. Zisman, and B. Bonavida. 2002. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 53, 286-299.
DOI
ScienceOn
|
43 |
Pan, G., J. Ni, Y. F. Wei, G. Yu, R. Gentz, and V. M. Dixit. 1997. An antagonist decoy receptor and a death domain- containing receptor for TRAIL. Science 277, 815-818.
DOI
ScienceOn
|
44 |
Jeremias, I. and K. M. Debatin. 1998. TRAIL induces apoptosis and activation of NFkappaB. Eur. Cytokine Netw. 9, 687-688.
|
45 |
Kim, H. G., Y. P. Hwang, and H. G. Jeong. 2009. Kahweol blocks STAT3 phosphorylation and induces apoptosis in human lung adenocarcinoma A549 cells. Toxicol. Lett. 187, 28-34.
DOI
ScienceOn
|
46 |
Kim, J.Y., K. S. Jung, K. J. Lee, H. K. Na, H. K. Chun, Y. H. Kho, and H. G. Jeong. 2004. The coffee diterpene kahweol suppress the inducible nitric oxide synthase expression in macrophages. Cancer Lett. 213, 147-154.
DOI
ScienceOn
|
47 |
Kirshner, J. R., A. Y. Karpova, M. Kops, and P. M. Howley. 2005. Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J. Virol. 79, 9320-9324.
DOI
ScienceOn
|
48 |
LeBlanc, H. N. and A. Ashkenazi. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death. Differ. 10, 66-75.
DOI
ScienceOn
|
49 |
Lee, T. J., E. M. Jung, J. T. Lee, S. Kim, J. W. Park, K. S. Choi, and T. K. Kwon. 2006. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol. Cancer Ther. 5, 2737-2746.
DOI
ScienceOn
|
50 |
Hofer-Warbinek, R., J. A. Schmid, C. Stehlik, B. R. Binder, J. Lipp, and M. R. de. 2000. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J. Biol. Chem. 275, 22064-22068.
DOI
|
51 |
Huang, M. T., R. C. Smart, C. Q. Wong, and A. H. Conney. 1988. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 48, 5941-5946.
|
52 |
Huber, W. W., S. Prustomersky, E. Delbanco, M. Uhl, G. Scharf, R. J. Turesky, R. Thier, and R. Schulte-Hermann. 2002. Enhancement of the chemoprotective enzymes glucuronosyl transferase and glutathione transferase in specific organs of the rat by the coffee components kahweol and cafestol. Arch. Toxicol. 76, 209-217.
DOI
ScienceOn
|